Merck Serono Submits Oral Cladribine But That Doesn't End The Oral MS Race
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck Serono's NDA filing will not prohibit a possible priority review for Novartis' oral FTY720, which had Phase III data released the same day; both applications face close scrutiny with less than ideal clinical trial packages.